冠状动脉支架植入术后阿托伐他汀防治再狭窄的实验临床研究.docxVIP

冠状动脉支架植入术后阿托伐他汀防治再狭窄的实验临床研究 　　[摘要] 目的 分析冠状动脉支架植入术后阿托伐他汀应用下对预防再狭窄的效果进行分析。方法 方便选取医院XX年1月―XX年1月收治的行冠脉植架患者86例，采用随机划分方法分为对照组与观察组各43例，观察组冠状动脉支架植入术后给予阿托伐他汀，观察比较两组患者治疗效果、植架情况。 结果 两组患者术前TC、TG、APN等指标差异无统计学意义，术后观察组TC、TG、APN等指标改善明显优于对照组，比较差异有统计学意义。观察组支架内管腔密度值HU小于对照组HU，支架内径mm长于对照组mm，比较差异有统计学意义。 结论 阿托伐他汀用于冠脉植架患者中，对预防再狭窄情况可发挥重要作用，应在临床实践中推广应用。　　[关键词] 阿托伐他汀；冠脉植架；再狭窄　　[中图分类号] R541 [文献标识码] A [文章编号] 1674--0111-03　　[Abstract] Objective To analyze the effect of atorvastatin in prevention and treatment of restenosis after the coronary stent implantation. Methods 86 cases of patients with coronary stent implantation admitted and treated in our hospital from January XX to January XX were selected and randomly divided into two groups with 43 cases in each， the observation group were treated with atorvastatin after the coronary stent implantation， and the treatment effect and stent of the two groups were observed and compared. Results The differences in the TC，TG，APN between the two groups before surgery were not statistically significant， and the improvement of TC，TG，APN in the observation group after surgery was obviously better than that in the control group， and the difference was obvious by comparison， and the internal lumen density value was less than that in the control group， [HU vs HU]， and the stent diameter was longer than that in the control group， [mm vs mm]， and the differences were obvious， with statistical significance. Conclusion The atorvastatin plays an important role in preventing the restenosis of patients with coronary stent implantation， which can be promoted and applied in clinic.　　[Key words] Atorvastatin； Coronary stent； Restenosis　　作?榱俅渤＜?心血管疾病，冠状动脉粥样硬化患者治疗中主要针对冠状动脉狭窄治疗，常用的治疗手段得以植入支架方式为主，确保患者心肌供血恢复，改善临床症状。但值得注意的是，从大多支架植入患者术后情况，一般在3～6个月内出现支架内再狭窄的可能性极高，这种再狭窄问题的发生不仅影响患者预后，且可能需重新植入支架，患者承受的身心压力与经济负担均增大。对此，可考虑在冠状动脉支架植入术后给予阿托伐他汀预防。该次研究将就XX年1月―XX年1月收治的行冠脉植架患者86例阿托伐他汀的应用效果进行分析，现报道如下。　　1 资料与方法　　 一般资料　　方便选取医院收治的行冠脉植架患者86例，男48例，女38例，年龄52～65岁，平均岁，疾病类型：稳定型心绞痛、不稳定型心绞痛与急性心